Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
3.72
-0.17 (-4.37%)
After Hours: 3.72 0.00 (0.00%)
Apr 23, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.70 - 3.92
52 week 3.20 - 7.45
Open 3.90
Vol / Avg. 602,632.00/1.27M
Mkt cap 258.82M
P/E     -
Div/yield     -
EPS -0.78
Shares 69.58M
Beta 1.15
Inst. own 86%
Apr 8, 2014
Progenics Pharmaceuticals at Needham Healthcare Conference
Mar 13, 2014
Q4 2013 Progenics Pharmaceuticals Earnings Release
Mar 13, 2014
Q4 2013 Progenics Pharmaceuticals Earnings Conference Call - Webcast
Feb 10, 2014
Progenics Pharmaceuticals at Biotechnology Industry Organization CEO & Investor Conference
Jan 30, 2014
Progenics Pharmaceuticals to Discuss Phase 2 Data From Two Trials in Prostate Cancer Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -288.11% -541.49%
Operating margin -300.64% -546.68%
EBITD margin - -534.74%
Return on average assets -28.94% -44.61%
Return on average equity -41.36% -58.50%
Employees 76 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Paul J. Maddon M.D., Ph.D. Vice Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Hagop Youssoufian M.D. Executive Vice President - Research & Development
Bio & Compensation  - Reuters
John W. Babich PhD Senior Vice President
Age: 55
Bio & Compensation  - Reuters
Robert J. Israel M.D. Senior Vice President - Medical Affairs & Clinical Research
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 60
Bio & Compensation  - Reuters
Angelo W Lovallo Jr Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 57
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Vice President - Product Development
Age: 55
Bio & Compensation  - Reuters